SGMOQ

SEC source: 0001209191-20-039346 · doc4.xml · derivative · entry 2

McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-06-24

F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the June 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-039346 · doc4.xml · nonDerivative · entry 1

McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: Includes 100,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on June 25, 2020. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such dates and subject to acceleration as defined in the 2018 EIP, as amended.

SEC source: 0001209191-20-034882 · doc4.xml · derivative · entry 3

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2

Underlying: Common Stock · 14,907 shares

Expires 2020-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · derivative.exercise_price: (or 80,000 Subject Free Shares) (the "Second Tranche Shares") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

F1 · derivative.underlying_shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · derivative.underlying_shares: (or 80,000 Subject Free Shares) (the "Second Tranche Shares") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

SEC source: 0001209191-20-034882 · doc4.xml · nonDerivative · entry 2

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,116

F1 · shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · shares: (or 80,000 Subject Free Shares) (the "Second Tranche Shares") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

SEC source: 0001209191-20-034882 · doc4.xml · nonDerivative · entry 1

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,023

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · shares: (or 80,000 Subject Free Shares) (the "Second Tranche Shares") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

F1 · price: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · price: (or 80,000 Subject Free Shares) (the "Second Tranche Shares") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

SEC source: 0001209191-20-030966 · doc4.xml · derivative · entry 2

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-17

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-20-030966 · doc4.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-030965 · doc4.xml · derivative · entry 2

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-17

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-20-030965 · doc4.xml · nonDerivative · entry 1

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021, (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

F2 · balance_after: Includes 3,333 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing two remaining vesting tranches from such RSU grant. Such RSUs vest with respect to 1,666 shares on June 26, 2020 and 1,667 shares on June 26, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.

SEC source: 0001209191-20-030961 · doc4.xml · derivative · entry 2

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-17

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-20-030961 · doc4.xml · nonDerivative · entry 1

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-030959 · doc4.xml · derivative · entry 2

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-17

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-20-030959 · doc4.xml · nonDerivative · entry 1

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-030956 · doc4.xml · derivative · entry 2

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-17

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-20-030956 · doc4.xml · nonDerivative · entry 1

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

F2 · balance_after: Includes 5,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 22, 2019. Such RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-030948 · doc4.xml · derivative · entry 2

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-17

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-20-030948 · doc4.xml · nonDerivative · entry 1

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-030947 · doc4.xml · derivative · entry 2

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-17

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-20-030947 · doc4.xml · nonDerivative · entry 1

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-034015 · doc4a.xml · derivative · entry 2

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-17

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034015 · doc4a.xml · nonDerivative · entry 1

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

SEC source: 0001209191-20-034033 · doc4a.xml · derivative · entry 2

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-17

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034033 · doc4a.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

SEC source: 0001209191-20-034029 · doc4a.xml · derivative · entry 2

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-17

F4 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034029 · doc4a.xml · nonDerivative · entry 1

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

F3 · balance_after: Includes 3,333 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing two remaining vesting tranches from such RSU grant. Such RSUs vest with respect to 1,666 shares on June 26, 2020 and 1,667 shares on June 26, 2021, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended) through such dates and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034022 · doc4a.xml · derivative · entry 2

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-17

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034022 · doc4a.xml · nonDerivative · entry 1

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

SEC source: 0001209191-20-034026 · doc4a.xml · derivative · entry 2

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-17

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034026 · doc4a.xml · nonDerivative · entry 1

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

SEC source: 0001209191-20-034020 · doc4a.xml · derivative · entry 2

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-17

F4 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034020 · doc4a.xml · nonDerivative · entry 1

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

F3 · balance_after: Includes 5,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 22, 2019. Such RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended) through such date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034013 · doc4a.xml · derivative · entry 2

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-17

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-20-034013 · doc4a.xml · nonDerivative · entry 1

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

SEC source: 0001209191-20-044347 · doc4.xml · derivative · entry 1

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2

Underlying: Common Stock · Not disclosed shares

Expires 2020-05-09

F1 · derivative.exercise_price: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning May 3, 2019 (the "Free Shares Call Options"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On May 9, 2020, the Free Shares Call Option with respect to the second tranche of Subject Free Shares (or 80,000 Subject Free Shares) expired unexercised.

F1 · derivative.underlying_shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning May 3, 2019 (the "Free Shares Call Options"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On May 9, 2020, the Free Shares Call Option with respect to the second tranche of Subject Free Shares (or 80,000 Subject Free Shares) expired unexercised.

SEC source: 0001209191-20-026045 · doc4.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,603

F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on April 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on April 24, 2020 of $8.32/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan.

F2 · balance_after: Includes: 1,270 shares resulting from the April 25, 2020 vesting of Reporting Person's April 25, 2019 restricted stock unit ("RSU") grant; 3,833 shares subject to such RSU grant that will vest in two remaining annual installments on April 25, 2021 and 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; 16,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020; and 3,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on March 25, 2020. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-021346 · doc4.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,250

F1 · shares: Represents 3,000 shares subject to restricted stock units granted on March 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

F2 · balance_after: Includes 5,750 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on April 25, 2019 and 16,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020. All such RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-020483 · doc4.xml · derivative · entry 3

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2020-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant.

SEC source: 0001209191-20-020483 · doc4.xml · nonDerivative · entry 2

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 15, 2019.

F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $6.00 to $6.02 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-020483 · doc4.xml · nonDerivative · entry 1

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.

SEC source: 0001209191-20-020353 · doc4.xml · nonDerivative · entry 1

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,000

F1 · balance_after: Includes 2,500 shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date(s).

SEC source: 0001209191-20-020303 · doc4.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.

SEC source: 0001209191-20-020143 · doc4.xml · derivative · entry 3

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 15,000 shares

Expires 2020-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant.

SEC source: 0001209191-20-020143 · doc4.xml · nonDerivative · entry 2

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 15, 2019.

F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $6.00 to $6.20 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-020143 · doc4.xml · nonDerivative · entry 1

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.

SEC source: 0001209191-20-019005 · doc4.xml · nonDerivative · entry 2

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.

SEC source: 0001209191-20-019005 · doc4.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.

SEC source: 0001209191-20-013230 · doc4.xml · derivative · entry 2

Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,500

Underlying: Common Stock · 100,500 shares

Expires 2030-02-24

F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-20-013230 · doc4.xml · nonDerivative · entry 1

Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,750

F1 · shares: Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-013239 · doc4a.xml · derivative · entry 2

Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2030-02-02

F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-20-013239 · doc4a.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,250

F1 · shares: Represents 16,500 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person on October 31, 2019 under the Issuer's 2010 Employee Stock Purchase Plan, as amended.